[1]龚淑芬*,李雪莲,宋志红.硫酸镁联合硝苯吡啶对妊娠期高血压疾病的治疗效果及对妊娠相关蛋白A、血液流变学的影响[J].中国计划生育和妇产科,2018,(7):85-89.
　GONG Shu-fen*,LI Xue-lian,SONG Zhi-hong.Effects of magnesium sulfate combined with nifedipine on hypertensive disorder complicating pregnancy and its effects on pregnancy associated plasma protein A and hemorheology[J].Chinese Journal of Family Planning & Gynecotokology,2018,(7):85-89.
点击复制

硫酸镁联合硝苯吡啶对妊娠期高血压疾病的治疗效果及对妊娠相关蛋白A、血液流变学的影响
分享到：

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2018年7期
页码:
85-89
栏目:
论著与临床
出版日期:
2018-07-25

文章信息/Info

Title:
Effects of magnesium sulfate combined with nifedipine on hypertensive disorder complicating pregnancy and its effects on pregnancy associated plasma protein A and hemorheology
作者:
龚淑芬*; 李雪莲; 宋志红
达川区人民医院妇产科
Author(s):
GONG Shu-fen*;  LI Xue-lian;  SONG Zhi-hong
Department of Obstetrics and Gynecology,Dachuan District People's Hospital,Dazhou Sichuan 635000,P.R.China
关键词:
硫酸镁; 硝苯吡啶; 妊娠期高血压疾病; 血液流变学; 内皮功能
Keywords:
magnesium sulphate; nifedipine; hypertensive disorder complicating pregnancy ; hemorheology; endothelial function
分类号:
R 71424+6
摘要:
目的观察硫酸镁联合硝苯吡啶对妊娠期高血压疾病的临床疗效及对妊娠相关蛋白A（pregnancy associated plasma protein A, PAPP-A）、血液流变学的影响。方法选择2014年12月至2016年12月达州市达川区人民医院收治的妊娠期高血压疾病患者345例，根据入院先后顺序分为观察组（173例）和对照组（172例）。对照组患者采用25 % 硫酸镁静脉滴注，控制每日硫酸镁摄入量为25～30 g，观察组在对照组治疗基础上口服硝苯吡啶片，10 mg/次，Q 8 H，连续治疗5~7 d。观察两组患者治疗前后血压、血流动力学指标、PAPP-A、总抗氧化能力（total antioxidant capacity,TAC）、血管内皮功能水平变化情况。结果治疗前，两组患者血压、血液流变学指标水平比较差异无统计学意义（P>005）。治疗1个疗程后，观察组血压、全血黏度（高切、中切、低切）和全血还原黏度（高切、中切、低切）水平均低于对照组（P<005）。治疗前，两组PAPP-A、TAC、血管内皮生长因子（vascular endothelial growth factor，VEGF）、内皮素（endothelin，ET）、一氧化氮(nitric oxide, NO)水平比较差异无统计学意义（P>005）。治疗1个疗程后，观察组PAPP-A、VEGF、ET水平低于对照组，TAC、NO水平高于对照组（P<005）。两组不良反应发生率比较差异无统计学意义（P>005）。结论硫酸镁联合硝苯吡啶治疗妊娠期高血压疾病可有效降低血压，改善血液流变学水平和血管内皮功能，降低血清PAPP-A水平，且不增加不良反应，安全性较高。
Abstract:
ObjectiveTo observe the clinical curative effect of magnesium sulfate combined nifedipine on hypertensive disorder complicating pregnancy(HDCP) and on pregnancy associated plasma protein A(PAPP-A) and the hemorheology.Methods345 patients with HDCP treated in Dachuan District People's Hospital from December 2014 to December 2016 were divided into the control group(172 cases) and the observation group(173 cases) according to the order of admission. The control group were treated by intravenous infusion of 25 % magnesium sulfate, magnesium sulfate daily intake of 25~30 g.The observation group were treated with oral nifedipine tablets on the basis of treatment in the control group, 10 mg each time, Q8H, continuous treatment for 5~7 days. The changes of blood pressure, hemodynamic parameters, PAPP-A, total antioxidant capacity(TAC) and vascular endothelial function before and after treatment were observed in both groups. ResultsBefore treatment, there was no significant difference in blood pressure and hemorheology indexes between the two groups (P>005). After one course of treatment, the blood pressure, whole blood viscosity (high cut, middle cut, low cut) and whole blood reduced viscosity (high cut, middle cut, low cut) in the observation group were lower than those in the control group (P<005). Before treatment, the levels of PAPP-A, TAC, vascular endothelial growth factor (VEGF), endothelin (ET), and nitric oxide (NO) were not significantly different between the two groups (P> 005). After one course of treatment, the levels of PAPP-A, VEGF, and ET were lower in the observation group than in the control group, and the levels of TAC and NO were higher in the observation group than in the control group (P<005). There was no significant difference in the incidence of adverse reactions between the two groups(P>005).ConclusionMagnesium sulfate combined with nifedipine in the treatment of HDCP can effectively reduce blood pressure, improve blood rheology and vascular endothelial function, reduce serum PAPP-A levels, without increasing adverse reactions,and is of high safety.

参考文献/References:

［1］CLARK S M, DUNN H E, HANKINS G D. A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy ［J］. Seminars in Perinatology, 2015, 39(7): 548-555. ［2］宋苹．硝苯地平控释片联合硫酸镁对妊娠期高血压的治疗价值分析 ［J］．重庆医学，2017，46（1）：363-364． ［3］秦雯．硫酸镁三联用药方案治疗妊娠期高血压疾病疗效观察及对妊娠结局的影响 ［J］．中国妇幼保健，2014，29（26）：4230-4232． ［4］袁雪梅．酚妥拉明、硝苯地平、硫酸镁联合用药对妊娠高血压综合征的效果观察 ［J］．吉林医学，2014，35（34）：7635-7636． ［5］王敏侠，王静，沈艳艳．妊娠期高血压合并HELLP综合征患者临床治疗分析 ［J］．中国妇幼保健，2013，28（27）：4464-4466． ［6］SHEKHAR S, GUPTA N, KIRUBAKARAN R, et al. Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis ［J］. BJOG : an International Journal of Obstetrics and Gynaecology, 2016, 123(1): 40-47. ［7］高宇，折瑞莲，黎燕．硫酸镁联合硝苯地平治疗对妊娠期高血压疾病患者血清Hcy和CRP的影响 ［J］．中国妇幼保健，2014，29（6）：859-861． ［8］李璐．硫酸镁联合硝苯地平治疗妊娠高血压综合征的疗效及对分娩结局的影响 ［J］．中国现代药物应用，2015，9（13）：129-130． ［9］李力，张欣．妊娠期高血压疾病的规范化治疗策略 ［J］．实用妇产科杂志，2014，30（6）：407-410． ［10］詹前美，胡宏波，冯金，等．硝苯地平联合硫酸镁对妊娠期高血压综合征患者肾功能及凝血指标的影响 ［J］．国际检验医学杂志，2017，38（14）：1950-1952． ［11］黄静，史霞．硝苯地平联合硫酸镁治疗妊高症的疗效及安全性评价 ［J］．中国组织工程研究，2016，20（2）：242． ［12］崔艳华．硫酸镁联合硝苯地平及酚妥拉明治疗妊娠高血压综合征的疗效 ［J］．中国实用神经疾病杂志，2017，20（9）：121-123． ［13］WEBSTER L M, MYERS J E, NELSON-PIERCY C, et al. Labetalol versus nifedipine as antihypertensive treatment for chronic hypertension in pregnancy novelty and significance ［J］. Hypertension, 2017, 70(5): 915-922. ［14］SHI Qingquan, LENG Wenying, YAO Qiang, et al. Oral nifedipine versus intravenous labetalol for the treatment of severe hypertension in pregnancy ［J］. International Journal of Cardiology, 2015, 178(6): 162-164.

相似文献/References:

[1]廖运先,王晨虹.妊娠期高血压疾病硫酸镁及降压药的应用[J].中国计划生育和妇产科,2016,(05):0.
[2]杨孜.妊娠期高血压疾病中使用硫酸镁的种种问题及思考[J].中国计划生育和妇产科,2017,(8):1.
[3]刘丽华*,杨华,赵玉字.硫酸镁与高压氧联合治疗胎儿宫内发育迟缓效果及对孕妇外周血中一氧化氮水平和前列腺素水平的影响[J].中国计划生育和妇产科,2019,(3):49.
　LIU Li-hua*,YANG Hua,ZHAO Yu-zi.Effect of magnesium sulfate combined with hyperbaric oxygen on intrauterine growth retardation and its effect on NO level and prostaglandin level in maternal peripheral blood[J].Chinese Journal of Family Planning & Gynecotokology,2019,(7):49.

更新日期/Last Update: 2018-07-25